Exploring the impact of adult obesity in Spain: Insights from a systematic literature review Authors: Jennifer Redondo-Antón, Silvia Díaz-Cerezo, Esther Artime, Miriam Rubio-de Santos, Miguel Ángel Rubio-Herrera Published: 2026 ABSTRACT AbstractBackgroundSpain ranks among the European countries with the highest obesity prevalence, yet the evidence on the full spectrum of its impact has not been systematically consolidated.MethodsThis was a systematic literature review (SLR) conducted to evaluate the epidemiological, clinical, humanistic, and economic impact of obesity in Spain. Embase® and MEDLINE® were searched for relevant publications from January 1, 2018, to August 17, 2025.ResultsA total of 54 records reporting on 53 studies were selected for inclusion. These covered (1) Epidemiology of obesity in Spain (n = 24); (2) Patient characteristics and obesity management (n = 7); (3) Obesity-related complications (n = 13); (4) Humanistic impact of obesity (n = 10); (5) Economic burden (n = 7); (6) Perceptions and attitudes about obesity (n = 4); and (7) Local policies and recommendations (n = 7). The prevalence of obesity (defined as a body mass index [BMI] ≥30 kg/m2) varied considerably according to study setting and methodology, ranging from 25% to 34% in primary care settings and from 11% to 22% in general population studies. The most frequent obesity-related complications included hypertension, dyslipidemia, type 2 diabetes, cardiovascular disease, and chronic kidney disease. Evidence suggested that people with obesity and overweight may have lower quality of life than those without obesity and overweight. The economic burden of obesity was high in Spain, with costs decreasing as BMI decreased. Included studies highlighted several barriers to obesity care in Spain, including stigma, mental health, funding/resources, education, and misconceptions. Recommendations to overcome these barriers included early prevention, patient engagement, shared decision-making, communication, and recognition of obesity as a chronic disease.ConclusionThis review reveals a consistent and multi-level gap between the documented burden of obesity in Spain and its identification, treatment, and prioritization within the healthcare system. Addressing this gap will require coordinated efforts across clinical documentation, therapeutic intervention, patient education, and health policy.Keywords: Burden of disease, Economics, Epidemiology, Obesity, Prevalence, Spain Introduction Obesity is a global public health concern with a rising prevalence reaching epidemic proportions and ranking as the fifth leading cause of death worldwide [1,2]. The World Health Organization (WHO) defines obesity as a chronic relapsing disease linked to abnormal or excessive fat accumulation, resulting in a body mass index (BMI) ≥30 kg/m2 [2]. The European Association for the Study of Obesity (EASO) 2024 diagnostic framework provides a more nuanced diagnostic definition, outlining the following criteria: BMI ≥30 kg/m2 or a BMI of 25–29.9 kg/m2 with a waist-to-height ratio of ≥0.5 and at least one obesity-related medical, functional, or psychological comorbidity [3]. The widespread impact of obesity encompasses an individual's health, well-being, and financial stability. People with obesity (PwO) and people with overweight experience a significant burden in terms of obesity-related complications (ORCs), including chronic diseases such as type 2 diabetes (T2D), heart disease, chronic kidney disease (CKD), low back pain, and stroke [4]. These comorbidities contribute to millions of deaths globally each year, with Global Burden of Disease estimates attributing approximately 3–4 million deaths annually to high BMI [1,[4], [5], [6]]. Obesity also results in a significant economic burden for healthcare systems globally. A 2017 systematic literature review (SLR) including quantitative data from 34 studies from several countries showed that the median increase in mean total annual healthcare costs for PwO compared with individuals without overweight/obesity was 36.0%, mainly due to increased costs for medications (68.0%) and inpatient care (34.0%) [7]. PwO may also have impaired mental health, as evidenced by a bidirectional link between depression and obesity [8]. Weight stigmatization exacerbates depression among PwO, contributing to low self-esteem and hindering access to healthcare services [9]. The complexity of the pathophysiology of obesity, involving food intake, metabolism, energy expenditure, and physical activity, is influenced by various socio-cultural, economic, dietary, genetic, environmental, and psychosocial factors [10,11]. This complexity demands a multidisciplinary approach, as highlighted by clinical practice guidelines and national public health strategies [10,12,13]. Implementing obesity policies to destigmatize obesity and promote preventive interventions at the population level should be combined with patient-centered lifestyle interventions as the cornerstone of obesity management, as well as tailored psychological, pharmacologic, and surgical approaches to achieve individual health or obesity management goals [10,12,13]. Obesity medications with variable success rates and safety profiles are available and recommended but not reimbursed in Spain, including glucagon-like peptide-1 (GLP-1) receptor agonists, such as liraglutide and semaglutide, and the glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist tirzepatide. Additionally, in Spain, bariatric surgery may be considered for PwO with a BMI ≥35 kg/m2 and individuals with metabolic disease and a BMI of 30–34.9 kg/m2 after evaluation by a multidisciplinary team [6,10]. Despite the rising prevalence of obesity, the associated mortality risk, and its impact on healthcare services, a comprehensive review of its burden and management in Spain is lacking. Identifying existing evidence gaps and barriers to obesity management from the literature is essential for effective planning of health resources and policies. In this context, the present SLR aims to gather available evidence on the epidemiological, clinical, humanistic, and economic impact of obesity in Spain, as well as identify any weight control programs and policies published in Spain. Methods This was an SLR conducted following best-practice guidelines as described by the Cochrane Collaboration guidance and reported in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA; Table S1). This SLR was performed in the context of a multiregional review, including Europe, Canada, and Asia-Pacific regions, the results of which are reported separately elsewhere [14,15]. Data sources and selection criteria The OVID search platform was used to search the Embase® and MEDLINE® and Epub Ahead of Print, In-Process, In-Data-Review, and other non-indexed citations and daily databases. Searches were conducted on December 14, 2022, covering publications from January 1, 2018, to December 14, 2022, and repeated on August 20, 2025, covering publications from December 14, 2022, to August 17, 2025, a total of 7.5 years. The search terms used a combination of free-text searching and medical “major subject headings” to identify publications with relevant terms as major topics. Terms used are included in Table S2 and Table S3. Additionally, an extensive grey literature search was performed, including abstract retrieval from key European and national congresses and targeted web-based searches. Selected Spanish congresses included the Spanish Society for the Study of Obesity Congress (2021–2024) and the National Congress of the Spanish Society of Endocrinology and Nutrition (2021–2024). Search terms included “prevalence,” “weight loss,” “quality of life/health-related quality of life,” “cost,” and “management.” Observational studies published in English and/or Spanish from January 1, 2018, to August 17, 2025, and conducted entirely in Spain or involving multiple countries but providing disaggregated data for the Spanish population were included. Abstracts published between 2021 and 2025 were included if they met the aforementioned criteria. Clinical trials, case series/reports, editorials, commentaries, notes, news articles, reviews, meta-analyses, intervention-specific economic models, and studies focusing on a specific medication or surgical intervention were excluded. In addition to the systematic search described above, further searches were undertaken to identify information on weight-control programs and policies published in Spain. Any publications identified in the above search that contained this information were retained, along with publications identified from additional grey literature searches, including websites of health technology assessment bodies and government agencies/societies; document types included clinical guidelines and algorithms, consensus documents, weight management protocols and programs, guidance and strategies and reports. Study selection, data extraction, and analysis Two reviewers independently screened and selected articles according to the inclusion and exclusion criteria. Disagreements were resolved by consensus or with the involvement of a third reviewer. Data from the articles were extracted by a single reviewer, and then data quality was checked by a second reviewer. From each selected article, the following data were extracted and tabulated: study design (including study type, country, data collection period, and data source), patient characteristics and management, epidemiological data (including incidence and prevalence rates and morbidity), humanistic burden (such as validated patient-reported and physician-reported outcomes, including health impact and productivity outcomes, and validated disease-specific and generic measures), and economic burden (resource utilization and costs, including direct costs, such as pharmacological costs, and indirect costs, such as non-medical costs and productivity losses), as well as key points of interest from policies and guidelines. Data are summarized using frequencies and ranges from the included studies. Given the heterogeneity of the data, no meta-analysis or overall quantitative synthesis was undertaken. A protocol was prepared for this SLR; however, it was not registered in a public protocol database or made publicly available, as this is not a requirement typically applied to reviews of this scope. Results After duplicate removal, a total of 18,371 publications were identified from Embase and MEDLINE, with an additional 2603 from the grey literature and website searching. Of these, 54 publications reporting on 53 studies were selected for inclusion in this review [4,16]. Of these 53 studies, 39 were conducted in Spain, and the remaining 14 studies reported data for multiple countries, including Spain (Table 1). Fig. 1 provides the PRISMA diagram to show the selection process, combining the results of both searches. Table 1Publications, patients, and clinical characteristics of people with obesity (PwO) in Spain.Table 1StudyCountryStudy design/settingStudy objectiveData sourcePwO included in each publication, nMales, %Mean ± SD age, yearsBarcones-Molero et al. [17]SpainCohort studyImpact of obesity and weight gain on HRQoLUniversity graduates3817645.0 ± 11.4Diez et al. [18]SpainConsensus documentDevelop environmental recommendations to prevent obesityResidents of a low-income districtNANANAMarques et al. [19]EuropeCross-sectional studyTo provide current data regarding the prevalence of overweight and obesity of adults from 20 European countriesEuropean Social Survey (general population)NRNRNRTorres-Collado et al. [20]SpainCross-sectionalTo determine the prevalence of obesity according to three anthropometric indicesNutrition and Health Survey of the Valencian Community14145Median 48Arrospide et al. [21]SpainCross-sectional studyTo identify inequalities associated with HRQoLSpanish Health Survey3201NRNRCatalina-Romero et al. [22]SpainProspective cohort studyTo analyze impact of obesity/overweight on sick absenceICARIA healthy workers without an active sickness absence episode28,828NRNRCinza Sanjurjo et al. [23] aSpainObservational, longitudinalTo analyze obesity prevalence and its association with CV risk/diseaseIBERICAN clinical trial (primary care)17894660.2 ± 13.4Cinza-Sanjurjo et al. [24] aSpainObservational, longitudinalPrevalence of obesity in primary care patients and geographical distributionIBERICAN clinical trial (primary care)27213661.0 ± 13.3Krzysztoszek et al. [25]MultinationalObservational, descriptive studyTo assess epidemiology of adult obesity in EU countries compared with other regionsWHO statistical databaseNANANARamón-Arbués et al. [26]SpainCross-sectionalTo estimate prevalence of overweight/obesity in workers and its associations with comorbiditiesMAS Sociedad de Prevención436773NRJanssen et al. [27]EuropeModelling studyFuture prevalence of obesity in 18 European countries and the USANCD Risk Factor Collaboration studyNANANASalvador et al. [28] Vilarrasa et al. [29]SpainCross-sectional studyTo identify perceptions, attitudes, behaviors, and barriers to obesity management for PwO and HCPACTION-IO study15004845Trujillo-Garrido et al. [30] bSpainCohort studyTo examine implementation of guideline recommendations in routine clinical practice and to analyze changes in the BMI and comorbidities over a 5-year periodPrimary care2094265.8 ± 12.7Trujillo-Garrido et al. [31] bSpainCohort studyTo examine motivation to lose weight among PwO, primary care resources used to promote behavioral change, and patient-reported factors limiting weight lossPrimary care2094265.7 ± 12.7Grau del Valle et al. [32]SpainLongitudinal intervention studyTo analyze changes in self-esteem and weight after a dietary–psychological interventionEndocrinology and Nutrition Unit of Dr. Peset University Hospital (Valencia)271543.5 ± 11.0Herrera-Espiñeira et al. [33]SpainCross-sectional studyLooking at physical activity, dietary habits, and HRQoL in patients with obesity/overweightHospital inpatients17752Median 69 (IQR 55–80)RTI International and World Obesity Federation [34]MultinationalEconomic modelTo examine the economic impact of overweight and obesity over the next 40 years across eight countriesCountry-specific data from various sourcesNRNRNRde Hoyos et al. [35]SpainCross-sectional studyTo evaluate differences in health service use by BMI2017 NHSNRNRNRDiamantis et al. [36]EuropecNationwide SurveyAssociation between socioeconomic factors and overweight/obesity status in European countriesFeel4Diabetes study (general population)243NRNRPerez-Rodrigo et al. [37]SpainCross-sectional studyPrevalence of overweight and abdominal obesity and influence of sociodemographic and lifestyle factorsThe ENPE study (general population)13635064 years: n = 820 ≥65 years: n = 406Primo et al. [38]SpainCohort studyEffect of prescribed online physical exercise on anthropometric parameters, CV risk factors, and QoLWeb platform352946.4 ± 6.4Román Gómez et al. [39]SpainRetrospective observational studyComparing weight loss and therapeutic adherence between group and individual approachesNR289NR50Ruiz-García et al. [40]SpainCross sectional studyTo determine the prevalence of overweight/obesity, and association with cardiometabolic and renal risk factorsSIMETAP-OB (primary care)18334560.01 ± 15.60Sánchez et al. [41]SpainRetrospective observational studyTo determine the frequency of undiagnosed CKD by BMIILERVAS projectNRNRNRStival et al. [42]EuropePopulation-based surveyPrevalence and factors associated with overweight and obesity in EuropeGeneral populationNRNRNRAdmetla Dachs et al. [43]SpainCross-sectional studyTo assess obesity complicationsNational Center for Obesity and DevelopmentNRNRNRCiudin Mihai et al. [44]SpainRecommendations, e.g., HCPTo describe resources available and areas for improvement in obesity managementNANANANAEvans et al. [45]EuropebCross-sectional studyTo collect data on comorbidities, HCRU and weight-loss strategies from PwOThe RESOURCE survey450NRNRGrela Casal et al. [46]SpainCross-sectional studyTo look at the relationship between BMI and risk of heart disease, hypertension or T2DPharmacy visitorsNRNRNRGutierrez-Gonzalez et al. [47]SpainPopulation-based surveyTo estimate prevalences of adult obesity/overweight by sex and sociodemographic characteristicsENE-COVID study57,13147.3%NRHoogendoorn et al. [48]MultinationalMarkov modelTo estimate the long-term burden of obesity in five European countriesMultiple sourcesNRNRNRLuca et al. [49]SpainCross-sectional studyTo analyze differences in anthropometric measurements, body composition, weight history, and comorbidities by dieting historyComplex obesity clinic8463148.9 ± 12.58Morer et al. [50]SpainClinical guidelinesTo propose a new model of a collaborative and integrative approach in obesity careNANANANAOlarte Sanchez et al. [51]SpainCross-sectional studyTo investigate the role that emotions play in the development of obesityA sample of Spanish adultsNRNRNRPellicer-Rodriguez et al. [52]SpainCross-sectional studyTo assess biological, sociocultural, and economic factors in PwONational University of Girona, Trueta Hospital referral center3873245.5Feijoo et al. [53]SpainRetrospective trend analysisTo analyze obesity prevalence trendsSpanish National Health Survey and the European Health Survey in SpainNRNRNRFernandez-Alvarez et al. [54]TenerifeObservational studyAn analysis of educational interventions for PwOCenter for Basic Education10028NRGBD Adult BMI Collaborators [55]GlobalGBD framework studyTo provide updated estimates of adult overweight and obesity prevalence by age and sex for 204 countries and territories from 1990 to 2021, with forecasts extending to 20501350 data sources from 184 countries/territoriesNRNRNRKoskinas et al. [56]EuropeConsensus documentTo raise awareness of obesity-associated risks and provide guidance for prevention and optimal managementNANANANAMunoz Arenas et al. [57]SpainObservational cohort studyPrevalence of comorbidities associated with obesityObesity clinic1682648.4 ± 15.8Raftopoulou et al. [58]SpainComputational studyLinks between income and BMIENSENANANARodriguez et al. [59]SpainCross-sectional studyBurden of disease in terms of QoL and work productivity among people with overweight/obesityAdelphi Real World Obesity III Disease Specific Programme™666NRNRSalinas-Roca et al. [60]SpainCross-sectional observational studyAssociation between food insecurity and obesityLleida Food BankNRNRNRSalinas-Roca et al. [61]SpainCross-sectional studyPhysical activity habits of a representative sample of the Spanish adult populationGeneral population of adults in Spain surveyed onlineNRNRNRTome-Fernandez et al. [62]SpainCross-sectional studyInfluence of anthropometric variables on QoL of PwO and relationship with psychological variablesParticipants of two different research projects in severe obesity774245.12 ± 10.29World Obesity Federation [63]GlobalNationwide SurveyNAVariousNRNRNRZhou et al. [4]GlobalGBD framework studyTo analyze global trends and burden of high BMI from 1990 to 2021 by countryGlobal Health Data Exchange GBD Results ToolNRNRNRArtime et al. [64]MultinationalcReal-world, retrospective cohort studyTo characterize adults with overweight/obesity in seven European and Asia–Pacific countries (prevalent population)Spain LPD92,381NRNRBallesteros-Pomar et al. [65]SpainModelling studyComplications associated with obesity and the cost savings after a weight loss of 15% over 10 yearsGeneral populationNANANABreton et al. [66]SpainReal-world, retrospective cohort studySociodemographic, clinical and treatment characteristics of adults with overweight/obesity (incident population)Spain LPD13,4414446.1 ± 16.1Ferreira et al. [67]MultinationalcCross-sectional online surveyTo understand out-of-pocket expenditures and non-financial costs incurred by PwO to manage weightOnline using consumer panels76NANALecube et al. [16]SpainClinical guidelinesTo develop a multidisciplinary, all-inclusive obesity management guidelineNANANANAMoreno et al. [68]SpainCross-sectional studyAssociations between overweight/obesity and sociodemographic variables, and lifestyle factorsEESE 2020 survey, ENSE 2017 survey38196347 ± 9.9BMI, body mass index; CKD, chronic kidney disease; CV, cardiovascular; EESE, European Health Survey in Spain (Encuesta Europea de Salud para España); ENSE, National Health Survey (Encuesta Nacional de Salud de España); EU, European Union; GBD, Global Burden of Disease; HCP, healthcare professional; HCRU, healthcare resource utilization; HRQoL, health-related quality of life; IQR, interquartile range; LPD, longitudinal patient database; NA, not applicable; NHS, National Health Service; NR, not reported; PwO, people with obesity; QoL, quality of life; SD, standard deviation; T2D, type 2 diabetes; WHO, World Health Organization.aThese publications both report data from the same study.bThese studies used the same primary care population.cData are for the subset of patients from Spain included in the study. Publications, patients, and clinical characteristics of people with obesity (PwO) in Spain. BMI, body mass index; CKD, chronic kidney disease; CV, cardiovascular; EESE, European Health Survey in Spain (Encuesta Europea de Salud para España); ENSE, National Health Survey (Encuesta Nacional de Salud de España); EU, European Union; GBD, Global Burden of Disease; HCP, healthcare professional; HCRU, healthcare resource utilization; HRQoL, health-related quality of life; IQR, interquartile range; LPD, longitudinal patient database; NA, not applicable; NHS, National Health Service; NR, not reported; PwO, people with obesity; QoL, quality of life; SD, standard deviation; T2D, type 2 diabetes; WHO, World Health Organization. These publications both report data from the same study. These studies used the same primary care population. Data are for the subset of patients from Spain included in the study. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram depicting literature screening and inclusion process. aAll of these records were excluded in the first search; in the updated search, studies that did not include data for Spain were excluded at the screening stage. bThe second search identified one study reporting an update to a study identified in the first search; both are included here [23,24] as well as one full-text publication [45] that replaced an abstract identified in the first round. SLR, systematic literature review. Epidemiology of obesity in Spain A total of 24 publications reported on the epidemiology of obesity in Spain (Table S4) [[19], [20], [21], [22], [23], [24], [25], [26], [27],29,[35], [36], [37],40,42,47,52,53,55,58,63,64,66,68]. Across these publications, the prevalence of obesity (defined as a BMI ≥30 kg/m2) varied considerably according to the study setting and methodology, ranging from 25% to 34% in primary care settings [23,24,40] and from 11% to 22% in studies of the general population and selected subpopulations [19,21,[35], [36], [37],42,47,53] (Fig. 2). Additionally, prevalence estimates differed depending on whether direct anthropometric measurement or self-reported weight and height were used and on the anthropometric measure used (BMI, waist circumference, body fat percentage) [20,24]. More specifically, studies showed a higher prevalence of abdominal obesity than of obesity defined as a BMI ≥30 kg/m2, with one study finding that 55.6% of the patients studied met criteria for abdominal obesity (waist circumference ≥102 cm in men and ≥88 cm in women), compared with 33.7% based on BMI (≥30 kg/m2) [24], and a second study finding that 20.1% of adults aged 19–64 years met BMI-based obesity criteria compared with 66.1% for abdominal obesity criteria (waist-to-height ratio >0.5) [37]. Estimates of obesity prevalence in Spain in studies reporting prevalence data, with studies in primary care populations or in the general population [19,21,24,25,27,37,40,42,47,53]. aData for 2016. Note, studies were highly heterogeneous and definitions of obesity differed between studies, therefore the estimates are not directly comparable; rather, this figure provides a snapshot of estimated obesity prevalence across included studies. Several studies have identified sociodemographic factors associated with obesity prevalence, including higher rates among older adults, individuals with disabilities, and those with lower income or educational attainment; conversely, obesity prevalence tends to decrease with increasing education, income, and municipality size [40,47,52,58,68]. Additionally, a subanalysis of data from the ACTION-IO Spain study showed that PwO from autonomous communities with a higher obesity prevalence were younger and had lower incomes, higher unemployment, and fewer comorbidities, and fewer had higher education than PwO from communities with a lower obesity prevalence [29]. Dietary habits, such as high consumption of meat and sugary drinks, have also been linked to greater risk of overweight and obesity [68]. Regarding obesity classification, Class I obesity is the most prevalent of the obesity classes in Spain, with Class II and Class III obesity less frequent (Table S4) [22,23,26,40,64]. Only one study, the IMPACT-O Spain study, included incidence data, reporting 13,441 incident cases of obesity and 25,016 incident cases of obesity/overweight documented in electronic medical records in Spain between 2018 and 2020, among a total of 1,570,445 active people in the Spanish database used [66]. Of note, this study also highlighted that the recording of overweight/obesity in health records in Spain likely leads to underestimation because only 25% of subjects in Spain with active records in the database had a BMI measurement recorded [66]. Recent national and international reports included in the current review indicate that Spain ranks among the top European countries in terms of the proportion of adults with elevated BMI, with projections suggesting a continued increase in obesity rates over the coming decades [25,27,55,63]. While data specifically for obesity is limited, the World Obesity Atlas 2024 estimates that the number of Spanish adults with overweight (high BMI, ≥25 kg/m2) will rise from 25 million in 2020 to nearly 30 million by 2035 [63]. Additionally, other modeling studies, including the Global Burden of Disease Study 2021 [55], forecast that the age-standardized prevalence of overweight and obesity combined in Spain will continue to climb, with rates potentially reaching up to 67% in females and 77% in males by 2050 [25,27,55]. Patient characteristics and obesity management Patient characteristics and patient management were reported in 7 studies [30,39,49,54,60,61,66], 3 reporting lifestyle characteristics in Spain for PwO and people without obesity [49,60,61], and 4 reporting information regarding treatment approaches utilized in PwO in Spain [30,39,54,66]. One study found that sedentary behavior was reported by 32.1% of people with overweight or obesity and by 24.2% of those without [61], and another study showed that, among people attending a complex obesity clinic, a history of dieting was associated with a significantly higher BMI [49]. Furthermore, evidence indicates a substantially higher prevalence of obesity among individuals experiencing food insecurity (94%) than among those not experiencing food insecurity (6%) [60]. Findings of studies reporting data on management approaches utilized in PwO in Spain highlighted an infrequent use of obesity medications [30,54,66] or bariatric surgery [66], with diet and exercise management approaches reported to be the most frequent management interventions [30]. More specifically, in a single-center survey (100 PwO), 18% of PwO reported use of semaglutide or another GLP-1 receptor agonist [54], and a cohort study of 209 PwO attending primary care reported that 1.4% had a recorded prescription for obesity medications, with 80% of PwO having a diet prescription, and 89% a physical activity prescription [30]. In the IMPACT-O Spain study, there were no records of lifestyle interventions or bariatric surgery in either the cohort of people with overweight/obesity or the cohort of PwO, with 73 (0.3%) and 75 (0.6%) reports of GLP-1 receptor agonist interventions in these cohorts [66]. In addition, one study compared group therapy interventions with individual treatment approaches for obesity, noting that group therapy was associated with greater therapeutic adherence than the individual approach [39]. Obesity-related complications A total of 13 publications described the prevalence of ORCs (also termed comorbidities, complications or associated pathologies in the cited literature) in PwO in Spain [17,23,26,30,40,41,43,45,46,49,57,59,66]. Overall, the studies included in this SLR reported a high rate of ORCs in PwO in Spain, with both the RESOURCE survey of PwO aged ≥18 years (n = 450 PwO in Spain) and the IMPACT-O Spain study (n = 16,489 PwO in Spain) reporting that more than 60% of PwO had at least one ORC and that ≥17% had at least three ORCs [45,66]. The most common ORCs across the included studies, most of which were conducted in primary or secondary care settings, included hypertension, dyslipidemia, T2D, cardiovascular disease (CVD), and CKD (Fig. 3) [17,23,30,40,43,46,49,57,59,66]. Studies that included patients across the BMI spectrum reported that PwO were at greater risk of these than individuals with BMI <30 kg/m2 [17,23,40,41]. For example, the IBERICAN study in patients at increased cardiovascular and renal disease risk in a primary care setting reported a higher prevalence in PwO than in individuals with a BMI <30 kg/m2 for hypertension (63% vs 39%), diabetes mellitus (28% vs 15%), and all analyzed CVDs (21% vs 15%) [23]. The primary care SIMETAP-OB study reported an increased prevalence of hypertension (60% vs 30%) and a higher prevalence of hypercholesterolemia and metabolic syndrome in PwO than in individuals with a BMI <30 kg/m2 (71% vs 59% and 72% vs 32%, respectively). Furthermore, this increased risk of ORCs, specifically T2D (62% vs 28%) and heart disease (2.24-fold increased risk), has also been shown in people who were overweight compared with people without overweight/obesity [46]. Prevalence of individual obesity-related complications in people with obesity (PwO) in Spain in (a) studies reporting data for both people with and without obesity [17,23,40] and (b) all studies reporting data for people with obesity [17,23,30,40,49,57,59,66]. BMI, body mass index; CKD, chronic kidney disease; CVD, cardiovascular disease; OSA, obstructive sleep apnea. Note, studies were highly heterogeneous and definitions of obesity differed between studies, therefore the estimates are not directly comparable between studies. When evaluating complications by obesity class, hypertension and dyslipidemia were the most frequent complication in both males and females across all three obesity classes [26]. No publications analyzing the incidence of ORCs in Spain were identified. Humanistic impact of obesity In total, 10 publications including PwO in Spain reported data on the humanistic impact of obesity, including data on a range of patient-reported outcomes, such as health-related quality of life (HRQoL), depression, anxiety, stress, mental well-being, and self-esteem using obesity-specific and generic measures and instruments (Table 2) [4,17,21,32,33,38,51,59,62,67]. Table 2Humanistic burden of obesity in Spain as reported in included publications.Table 2StudyStudy designData collection periodPopulation description (number of patients)OutcomesKey findingsArrospide et al. [21]Cross-sectional study2011–2012Adults in Spain (n = 18,450)EQ-5D-5L•Mean utilities significantly lower in PwO than those without overweight/obesity•PwO less likely to be in perfect health than people without overweight/obesity in low (OR 0.71; 95% CI 0.52–0.67)* and middle (OR 0.74; 95% CI 0.61–0.91) social classesHerrera-Espiñeira et al. [33]Cross-sectional study2018–2020Hospitalized adults with overweight (n = 98) or obesity (n = 177)EQ-5D-5L•No significant differences in HRQoL between people with overweight and PwOTome-Fernandez et al. [62]Cross-sectional study2023–2024Spanish adults with obesity (n = 77)IWQOL-Lite•The only anthropometric variable showing statistical significance across all QoL measures was BMI•People with overweight had lower QoL than those without overweight/obesityPrimo et al. [38]Cohort study2021PwO (n = 35)SF-36•An online exercise intervention improved QoL, with significant improvement in general health (20.9 ± 4.1 points; p = 0.001), physical role (6.9 ± 0.9 points; p = 0.01), and mental health (14.0 ± 1.3 points; p = 0.01)Barcones-Molera et al. [17]Cohort study1999–2014Adults in Spain (n = 10,033, including 381 PwO)SF-36•Physical function, general health and physical component summary lower in people with overweight/obesity than in those withoutOlarte Sánchez et al. [51]Cross-sectional studyNRSpanish adults (NR)Patient-reported outcomes•Those with overweight showed higher levels of emotional eating and worse general health scores than those without overweightGrau del Valle et al. [32]Longitudinal interventional studyNRPwO (n = 27)Self-esteem•Psychological treatment was associated with reductions in weight and improvements in self-esteemFerreira et al. [67]Online survey2022Spanish adults with obesity (n = 76)Impact of obesity on life and career•Percentage of respondents who agree that obesity negatively impacts outside activities (68%), running a household (44%), social life (40%), work (34%), family life (37%), traveling (31%), and career prospects (32%)Rodríguez et al. [59]Cross-sectional study2023–2024PwO (n = 666)SF-36 WPAI•On average, subjects reported 19% of their work productivity and 30% of their daily activities were affected by overweight/obesity•Those with a BMI ≥40 kg/m2 had the lowest SF-36 scores and highest WPAI valuesZhou et al. [4]Global Burden of disease framework study2021People with BMI ≥25 kg/m2 (NR)Standardized deaths and DALYs due to high BMI•Age-standardized death rate per 100,000 (95% CI):−1990 = 40.41 (16.23–67.14)−2021 = 29.30 (12.00–47.59)−Relative change: −0.28 (−0.35 to −0.18)•Age-standardized DALYs rate per 100,000 (95% CI)−1990 = 1227.96 (455.79–2018.83)−2021 = 1198.68 (460.34–1914)−Relative change −0.02 (−0.12 to −0.07)*The upper bound of this confidence interval appears to be a reporting error in Arrospide et al., as this is lower than the point estimate. Note, studies were highly heterogeneous, therefore the results presented are not directly comparable between studies.BMI, body mass index; CI, confidence interval; DALY, disability-adjusted life-year; HRQoL, health-related quality of life; IWQOL-Lite, Impact of Weight on Quality of Life-Lite; NR, not reported; OR, odds ratio; PwO, people with obesity; QoL, quality of life; SF-36, Short-Form Health Survey-36; WPAI, Work Productivity and Activity Impairment Questionnaire. Humanistic burden of obesity in Spain as reported in included publications. •Mean utilities significantly lower in PwO than those without overweight/obesity Mean utilities significantly lower in PwO than those without overweight/obesity •PwO less likely to be in perfect health than people without overweight/obesity in low (OR 0.71; 95% CI 0.52–0.67)* and middle (OR 0.74; 95% CI 0.61–0.91) social classes PwO less likely to be in perfect health than people without overweight/obesity in low (OR 0.71; 95% CI 0.52–0.67)* and middle (OR 0.74; 95% CI 0.61–0.91) social classes •No significant differences in HRQoL between people with overweight and PwO No significant differences in HRQoL between people with overweight and PwO •The only anthropometric variable showing statistical significance across all QoL measures was BMI The only anthropometric variable showing statistical significance across all QoL measures was BMI •People with overweight had lower QoL than those without overweight/obesity People with overweight had lower QoL than those without overweight/obesity •An online exercise intervention improved QoL, with significant improvement in general health (20.9 ± 4.1 points; p = 0.001), physical role (6.9 ± 0.9 points; p = 0.01), and mental health (14.0 ± 1.3 points; p = 0.01) An online exercise intervention improved QoL, with significant improvement in general health (20.9 ± 4.1 points; p = 0.001), physical role (6.9 ± 0.9 points; p = 0.01), and mental health (14.0 ± 1.3 points; p = 0.01) •Physical function, general health and physical component summary lower in people with overweight/obesity than in those without Physical function, general health and physical component summary lower in people with overweight/obesity than in those without •Those with overweight showed higher levels of emotional eating and worse general health scores than those without overweight Those with overweight showed higher levels of emotional eating and worse general health scores than those without overweight •Psychological treatment was associated with reductions in weight and improvements in self-esteem Psychological treatment was associated with reductions in weight and improvements in self-esteem •Percentage of respondents who agree that obesity negatively impacts outside activities (68%), running a household (44%), social life (40%), work (34%), family life (37%), traveling (31%), and career prospects (32%) Percentage of respondents who agree that obesity negatively impacts outside activities (68%), running a household (44%), social life (40%), work (34%), family life (37%), traveling (31%), and career prospects (32%) •On average, subjects reported 19% of their work productivity and 30% of their daily activities were affected by overweight/obesity On average, subjects reported 19% of their work productivity and 30% of their daily activities were affected by overweight/obesity •Those with a BMI ≥40 kg/m2 had the lowest SF-36 scores and highest WPAI values Those with a BMI ≥40 kg/m2 had the lowest SF-36 scores and highest WPAI values •Age-standardized death rate per 100,000 (95% CI):−1990 = 40.41 (16.23–67.14)−2021 = 29.30 (12.00–47.59)−Relative change: −0.28 (−0.35 to −0.18) Age-standardized death rate per 100,000 (95% CI):−1990 = 40.41 (16.23–67.14)−2021 = 29.30 (12.00–47.59)−Relative change: −0.28 (−0.35 to −0.18) −1990 = 40.41 (16.23–67.14) 1990 = 40.41 (16.23–67.14) −2021 = 29.30 (12.00–47.59) 2021 = 29.30 (12.00–47.59) −Relative change: −0.28 (−0.35 to −0.18) Relative change: −0.28 (−0.35 to −0.18) •Age-standardized DALYs rate per 100,000 (95% CI)−1990 = 1227.96 (455.79–2018.83)−2021 = 1198.68 (460.34–1914)−Relative change −0.02 (−0.12 to −0.07) Age-standardized DALYs rate per 100,000 (95% CI)−1990 = 1227.96 (455.79–2018.83)−2021 = 1198.68 (460.34–1914)−Relative change −0.02 (−0.12 to −0.07) −1990 = 1227.96 (455.79–2018.83) 1990 = 1227.96 (455.79–2018.83) −2021 = 1198.68 (460.34–1914) 2021 = 1198.68 (460.34–1914) −Relative change −0.02 (−0.12 to −0.07) Relative change −0.02 (−0.12 to −0.07) *The upper bound of this confidence interval appears to be a reporting error in Arrospide et al., as this is lower than the point estimate. Note, studies were highly heterogeneous, therefore the results presented are not directly comparable between studies. BMI, body mass index; CI, confidence interval; DALY, disability-adjusted life-year; HRQoL, health-related quality of life; IWQOL-Lite, Impact of Weight on Quality of Life-Lite; NR, not reported; OR, odds ratio; PwO, people with obesity; QoL, quality of life; SF-36, Short-Form Health Survey-36; WPAI, Work Productivity and Activity Impairment Questionnaire. A total of 4 studies reported quality of life (QoL) outcomes for PwO, utilizing the EQ-5D-5L questionnaire, the 36-item Short-Form Survey (SF-36) or the Impact of Weight on QoL (IWQOL-Lite) questionnaire [17,21,33,62]. More specifically, two studies utilized the EQ-5D-5L questionnaire in PwO, with one study (n = 18,450) reporting a significant decrease in the likelihood of PwO being in perfect health compared with individuals with a BMI <25 kg/m2 [21], whereas a study in hospitalized patients showed no significant differences in HRQoL between people with overweight and those with obesity [33]. Similarly, in the SUN study (n = 10,033), mean scores of the SF-36 mental component summary and physical component summary domains were lower for people with overweight/obesity than for those without overweight/obesity [17], and a study in 35 sedentary PwO revealed that an online exercise intervention improved QoL, as measured by the SF-36 [38]. In the fourth study, the only anthropometric variable showing statistical significance across all QoL measures (on the IWQOL-Lite) was BMI, and people with overweight reported lower QoL, including psychological QoL, than those without overweight/obesity [62]. In total, 2 studies reported psychological and emotional factors in PwO [32,51], highlighting that, compared with individuals without overweight/obesity, those with overweight reported higher levels of emotional eating and worse general health scores [51], and psychological treatment was associated with reductions in weight and improvements in self-esteem [32]. Studies also demonstrated that obesity may negatively impact many aspects of the life of PwO, including their personal life and their careers [59,67]. In an analysis of data from the Global Burden of Disease Study 2021, researchers demonstrated that age-standardized deaths and disability-adjusted life-years due to high BMI (BMI ≥25 kg/m2) were relatively constant between 1990 and 2021 in Spain, with relative changes of −0.28 (95% confidence interval [CI] −0.35 to −0.18) and −0.02 (95% CI −0.12 to −0.07) [4]. Economic burden A total of 7 publications evaluated the economic burden associated with obesity in Spain (Table 3) [22,[33], [34], [35],48,65,67]. Outcomes included direct (e.g., hospitalization) and indirect (e.g., productivity losses) economic costs related to obesity, as well as lifetime costs associated with obesity and cost savings derived from weight loss. Table 3Economic burden of obesity in Spain as reported in included publications.Table 3Outcome categoryStudy typeData collection periodPopulationOutcomesKey findingsEconomic estimatesModel [34]2019Spanish populationCost of overweight/obesity•$US29 billion (2.09% GDP)Model [48]2020Adults aged 40 yearsLifetime healthcare costs per person•BMI 30 kg/kg2 = €166,633•BMI 35 kg/kg2 = €173,183Online survey [67]202276 Spanish adults with obesityAnnual costs per person•$US6840.90 (14% of household income): 63% direct, 22% indirect, 15% ORCsProspective cohort study (interview) [22]2012–2013173,120 healthy workers in SpainAbsenteeism (sickness absences)•Statistically significant upward trend in all-cause sickness absences with increasing BMIEconomic projectionsModel [34]NASpanish populationCost of overweight/obesity•Projected cost in 2060: $US61 billion (2.43% GDP)Economic impact of weight lossModel [65]2009–2024100,000 adults with obesity in SpainCost savings from 15% weight loss•Estimated overall savings of €105 million, mainly from decreases in T2D (23%) and arterial hypertension (22%) at 10 yearsModel [48]2020Adults aged 40 yearsChange in healthcare costs with reduction in BMI•€1563 per 1 BMI unit lost; +0.677 years life expectancyHealthcare resource utilizationCross-sectional study [35]2017Spanish National Health Survey: 7081 adultsService utilization for PwO vs. those without overweight/obesity in the last 12 months•Emergency admissions OR 1.251 (95% CI 1.081–1.499)•Hospital admissions OR 1.249 (95% CI 0.885–1.763)Cross-sectional study [33]2018–2020275 hospitalized adults with overweight (n = 98) or obesity (n = 177)Length of hospital stay•Median hospital stay:•People with overweight = 8 days (IQR 5–10)•PwO = 8 days (IQR 1–10.75)Note, studies were highly heterogeneous, therefore the results presented are not directly comparable between studies. BMI, body mass index; CI, confidence interval; GDP, gross domestic product; IQR, interquartile range; NA, not applicable; OR, odds ratio; ORC, obesity-related complications; PwO, people with obesity; T2D, type 2 diabetes. Economic burden of obesity in Spain as reported in included publications. •$US29 billion (2.09% GDP) $US29 billion (2.09% GDP) •BMI 30 kg/kg2 = €166,633 BMI 30 kg/kg2 = €166,633 •BMI 35 kg/kg2 = €173,183 BMI 35 kg/kg2 = €173,183 •$US6840.90 (14% of household income): 63% direct, 22% indirect, 15% ORCs $US6840.90 (14% of household income): 63% direct, 22% indirect, 15% ORCs •Statistically significant upward trend in all-cause sickness absences with increasing BMI Statistically significant upward trend in all-cause sickness absences with increasing BMI •Projected cost in 2060: $US61 billion (2.43% GDP) Projected cost in 2060: $US61 billion (2.43% GDP) •Estimated overall savings of €105 million, mainly from decreases in T2D (23%) and arterial hypertension (22%) at 10 years Estimated overall savings of €105 million, mainly from decreases in T2D (23%) and arterial hypertension (22%) at 10 years •€1563 per 1 BMI unit lost; +0.677 years life expectancy €1563 per 1 BMI unit lost; +0.677 years life expectancy •Emergency admissions OR 1.251 (95% CI 1.081–1.499) Emergency admissions OR 1.251 (95% CI 1.081–1.499) •Hospital admissions OR 1.249 (95% CI 0.885–1.763) Hospital admissions OR 1.249 (95% CI 0.885–1.763) •Median hospital stay: Median hospital stay: •People with overweight = 8 days (IQR 5–10) People with overweight = 8 days (IQR 5–10) •PwO = 8 days (IQR 1–10.75) PwO = 8 days (IQR 1–10.75) Note, studies were highly heterogeneous, therefore the results presented are not directly comparable between studies. BMI, body mass index; CI, confidence interval; GDP, gross domestic product; IQR, interquartile range; NA, not applicable; OR, odds ratio; ORC, obesity-related complications; PwO, people with obesity; T2D, type 2 diabetes. In 2019, the economic impact (defined as direct impact plus indirect impact) of overweight and obesity in Spain was estimated using a model developed by World Obesity and RTI International (2019 United States Dollar (USD) values) at $US29 billion, or 2.09% of gross domestic product; this was projected to increase to $US61 billion (2.43% of gross domestic product) by 2060 [34]. Additionally, using a Markov model, total lifetime healthcare costs in Spain for individuals aged ≥40 years (2020 costs, undiscounted and in the absence of any weight loss intervention) were estimated at €166,633 for people with a BMI of 30 kg/m2 and €173,183 for people with PwO (BMI 35 kg/m2) [48]. A total of 2 modelling studies estimated the potential economic benefits of weight loss in Spain. The Markov model described above [48] demonstrated that a 1-unit decrease in BMI was associated with a change in total lifetime costs of ‒€1563 and an increased life expectancy of 0.677 years. Similarly, Ballesteros-Pomar et al. [65] developed a weight loss benefit simulation model using the perspective of the Spanish National Health System (2024 costs) based on demographic data and obesity rates in the Spanish population. This model demonstrated that, for 100,000 individuals with a BMI of 30–50 kg/m2, a 15% weight loss would result in substantial reductions in the risk of ORCs, translating to cumulative savings of €105 million over a 10-year period, with the highest savings associated with decreases in T2D, arterial hypertension, and osteoarthritis. Extrapolating this finding to weight loss of 15% in all Spanish people with obesity (5,490,000 individuals aged 20–69 years with a BMI of 30–50 kg/m2) would result in an estimated cost saving of €8000 million. Looking specifically at costs associated with weight management in PwO in Spain, 1 multinational survey (n = 600) that included 100 Spanish participants demonstrated that mean annual out-of-pocket expenditure on weight management of any kind (including both direct and indirect costs) was $US7351 per year, with a value of $US6840.90 among this subgroup, or 14% of annual household income (values converted from local currency into 2021 USD) [67]. Of this total cost, direct costs (costs directly related to weight loss and/or weight management) and indirect costs (costs related to or as a result of living with obesity, such as mental health support, cost of home help) accounted for 63% and 22%, respectively, with the remaining 15% associated with ORCs. Additionally, in a sample of 7081 adults from the Spanish National Health Survey, people with a BMI ≥30 kg/m2 were at increased odds of requiring emergency admission (odds ratio [OR] 1.273; 95% CI 1.081–1.499) or hospital admission (OR 1.249; 95% CI 0.885–1.763) than individuals without overweight/obesity [35]. Perceptions and attitudes about obesity A total of 4 publications described the perceptions and attitudes about obesity of healthcare professionals (HCPs) and PwO [28,29,31,44]. The ACTION-IO study showed differences in perceptions of obesity between HCPs and PwO [28]. Although most HCPs recognized obesity as a chronic disease (85%), a substantial proportion of PwO did not (41%), often assuming full personal responsibility. Furthermore, an expert panel in Spain described a limited awareness of obesity as a chronic disease beyond the clinical setting, together with insufficient institutional support and resources, and reported gaps in screening, diagnosis, and shared decision-making processes [44]. Across studies, reported barriers to obesity management included communication gaps between HCPs and PwO, limited professional training, and patient-related factors such as low motivation and a lack of perceived need for weight loss [28,31,44]. In addition, PwO—particularly those living in communities with a higher obesity prevalence—reported economic barriers related to healthy eating, obesity-management medications, and bariatric surgery [29]. Local policies and recommendations Several policy-relevant documents related to obesity in Spain were identified [16,18,34,50,56]. These included European-level consensus statements, such as those issued by the European Society of Cardiology [56], which address prevention and public health action; national clinical guidelines, including the Spanish GIRO Guidelines [16], focused on obesity management; and additional publications describing models for the organization of obesity care within the healthcare system [50], as well as locally informed policy initiatives [18]. The European Society of Cardiology consensus statement on obesity and cardiovascular disease notes that “preventive measures should focus particularly on childhood and early adulthood and address socioeconomic disparities”, and points out the need for public health interventions, involving all HCPs, implemented at governmental, non-governmental and civil society levels [56]. RTI International and the World Obesity Federation highlight the World Obesity Federation ROOTS framework and calls on policy-makers to develop obesity policy and advocacy though Recognition of obesity, monitoring of Obesity, prevention of Obesity, Treatment of obesity and use of a Systems-based approach [34]. At a country level, the Spanish GIRO Guidelines, published in 2025, outline 121 recommendations for obesity management intended to improve the QoL of PwO and to reduce the burden of obesity on the Spanish healthcare system [16]. Discussion This SLR comprehensively summarizes the epidemiological, clinical, humanistic, and economic burden of obesity in Spain, as reported in publications between 2018 and 2025. The prevalence of obesity has been increasing for several decades in high-income countries, and the projected rates included in the current study suggest a continued rise in Spain in the coming years [25,27,55,63]. The reported overall prevalence of obesity in Spain differed, and not all studies reporting prevalence data could be summarized by simple prevalence rates because some reported absolute numbers and others combined overweight and obesity categories. Between-study differences in reported prevalence are most likely a result of variations in sampling methods, data sources, and definitions used. For example, as reported previously [[69], [70], [71]], studies utilizing direct measurements of BMI tend to report a higher prevalence than population-level studies, which frequently rely on self-reported weight and height measurements [35,37,53]. More specifically, although studies focusing on the general population reported prevalences around or <20% [19,21,[35], [36], [37],42,47,53], studies conducted in primary care settings revealed higher prevalences of 25–34% [23,24,35,37,40,53]. Individuals attending primary care are typically older [72,73], a group in which the prevalence of obesity is higher [40,47,68] and that presents more frequently with chronic conditions or risk factors associated with obesity, leading to greater representation than in the general population. In addition, PwO also tend to use healthcare services more frequently because of comorbidities and follow-up needs [24,28,74,75], which further contribute to increased detection in primary care. It is also worth noting the data showing that the prevalence of obesity among migrants in Spain exceeds that of the general population [76], which, with increasing immigration [77], can be expected to further increase the prevalence of obesity in Spain. Together, these factors position primary care as a key setting for obesity prevention and management, a role that has been recognized and described in the GIRO Guidelines [16]. Despite the differences between studies, these values are in line with age-standardized estimates for 2022 corresponding to Spain (15.7% [95% credible interval 13.1–18.3]) and regions with a high prevalence of obesity, such as Europe (22.6% [95% credible interval 21.8–23.5]), America (33.8% [95% credible interval 32.5–35.0]), and high-income countries (25.9% [95% credible interval 24.9–26.8]) according to the WHO Global Health Observatory based on data from 3663 population-based studies with 222 million participants worldwide [78,79]. Furthermore, both Spanish and European Health surveys reported an overall obesity prevalence of 15.7% (15.1–16.3) in Spain in 2020 [53], and the Spanish National Health System indicated a similar prevalence of 16% among adults in the same year [80]. Overall, the evidence points to a substantial and growing burden of obesity in Spain, with marked sociodemographic disparities. These findings underscore the need for comprehensive prevention and care programs involving medical, social, educational, and political interventions. Evidence from the present study showed that the prevalence of obesity appears to increase with age, frequently peaking among individuals aged >65 years [40,47,68], which could be attributable to age-related changes, such as a progressive increase in fat mass and decline in lean mass, decreased mobility, and a slower metabolism [81]. The publications included in this review reinforce that obesity is associated with an increased risk of health complications and is associated with several chronic comorbidities. Hypertension, dyslipidemia, T2D, CVD, and CKD were repeatedly reported in the studies as highly prevalent comorbidities across PwO in Spain [17,23,30,40,43,46,49,57,59,66]. Moreover, those who are overweight were also shown to be at increased risk of ORCs [46], further highlighting the importance of early diagnosis and treatment, even before progression to obesity [82]. This risk of complications was highlighted during the COVID-19 pandemic, during which patients with obesity were at increased risk of COVID-19-associated hospitalization, a risk that increased with increasing degree of obesity, with patients with Class III obesity also at increased risk of admission to intensive care units and of invasive mechanical ventilation [83]. Consequently, improving obesity management is crucial to minimizing these comorbidities, particularly given the findings of a recent study showing that prolonged exposure to excess adipose fat tissue contributed to the development of ORCs [84]. Patient engagement significantly influenced weight management for PwO [85,86]. Contrary to HCP beliefs, PwO are motivated to lose weight but identify barriers that limit their weight loss [28,29,31]. Barriers to behavior change should be addressed early in treatment, lifestyle interventions should be individualized, and predictors of adherence (e.g., unrealistic weight reduction goals) should be considered to improve treatment effectiveness and health outcomes. A shared decision-making approach, involving collaboration with PwO to establish realistic goals, is also essential [16]. Suggestions to promote treatment adherence included remote digital health technologies in conjunction with multidisciplinary counseling, combining nutritional and psychological programs, group therapy, mindfulness programs, further involvement of primary care professionals in the treatment and follow-up of PwO, and motivational interviewing to enhance patient adherence [6,10,12,13,30,32,39,87]. Importantly, several barriers remain that hinder obesity management, including negative perceptions of obesity, low mood/depression among PwO, insufficient funding/resources/education that disproportionately affects weight management services, and obesity being viewed as a lifestyle disorder rather than a chronic disease [13,28,29,31,88,89]. There is also evidence of an apparent disconnection between HCPs and PwO because of prevailing misconceptions and negative assumptions, resulting in weight stigmatization in healthcare and a sense of reluctance to offer support [9,28,90,91]. Poor communication between PwO and HCP delays weight reduction consultations, resulting in a mean delay of 6 years before discussing weight, reducing opportunities for early intervention and increasing the risk of developing associated comorbidities, shown to be present in most PwO [28]. Importantly, Spanish and European guidelines for obesity management favor a practical, patient-centered approach and emphasize the importance of HCP communication to enhance self-efficacy and motivation in PwO in a nonjudgmental manner; addressing negative perceptions of obesity at both a patient and provider level is crucial for reducing the psychological impact of obesity [[90], [91], [92], [93]]. Moreover, the WHO guidance highlights the importance of in-depth medical evaluations to inform treatment options for PwO with the utilization of a multidisciplinary team to manage both the physical and the psychological aspects of obesity [13]. HCPs treating PwO require specific medical education to avoid the underdiagnosis of obesity, yet one study in this review reported that only around half of the HCPs in primary care had read articles on obesity in the past year [28]. In addition, results of the ACTION-IO study in Spain suggest that PwO may have limited access to specialists, as only 29% of patients had ever discussed their weight with an endocrinologist [28]. These findings highlight the need for HCP education surrounding obesity management, improved access to healthcare, and the implementation of multidisciplinary approaches. Policies regarding obesity management are predominately focused on obesity prevention, acknowledging that public health regulation is required because of the widespread existence of obesogenic environments [34,50]. Economic policies, including sugar taxes and reduced costs for healthier alternatives, such as gluten-free foods and diabetic products, are approaches already adopted in Spain and other countries [94,95]. Similarly, different policies have targeted obesogenic environments (such as food, retail, digital, and physical environments that promote weight gain) advocating for improved and accessible green spaces for physical activity, transformation of sedentary workplaces, and improving the access to and affordability of existing sports facilities [50,70,96] Collectively, policies across European countries highlight the importance of avoiding stigmatization, increased access to healthcare via digital health, improving HCP–patient communication, and multidisciplinary or tailored obesity management programs [16,18,[90], [91], [92], [93]]. The economic burden of obesity is a growing issue, and PwO are likely to require more healthcare resources than individuals without overweight/obesity [7,35,96]. Indeed, ORCs contribute greatly to the economic burden of obesity on healthcare systems, with healthcare costs rising as the number of ORCs increases, including hospitalization costs and prescription burden [45]. It has also been recognized that the prevalence of complications increases in Class II/III obesity, which has been shown to be associated with higher direct healthcare costs in terms of hospitalizations, long-term service care needs, and indirect costs, including absenteeism and productivity losses [22,97]. Again, this increase in costs was also highlighted during the COVID-19 pandemic, with obesity associated with substantial excess costs [83]. The Organization for Economic Cooperation and Development reported that, across 52 countries, including Spain, being overweight or having obesity reduced the workforce by 54 million, of which 28 million is due to reduced employment, 18 million to presenteeism, and 8 million to absenteeism [98]. Further, a literature review from 2022 focusing on European countries reported an association between obesity and lower earnings, lower levels of employment, and a higher probability of entering sick leave or exiting from paid employment through a disability pension [99]. Thus, effective and comprehensive prevention and weight management programs are crucial for reducing the substantial economic burden associated with obesity. It is important to note that, although the papers included in the current review, and therefore the conclusions drawn, are specific to the Spanish population, findings from studies conducted in other countries, particularly the country-specific publications from the ACTION-IO study [[100], [101], [102], [103], [104], [105], [106], [107]], highlight similar delays in seeking treatment and similar perceptions, barriers, and stigma across populations, suggesting that the information presented in the current review may be applicable to obesity management beyond the Spanish population. Limitations Some limitations of this study should be acknowledged. The heterogeneity of the included studies was an obstacle to pooling data and prevented quantitative analysis. Moreover, evidence discussed in this review comes from a broad range of study types, including cross-sectional studies, mathematical model projections, and subjective patient and provider perceptions, which vary in their reliability and strength of evidence. Indeed, a formal bias assessment was not performed, and the results should therefore be interpreted with caution, particularly where conclusions are informed by evidence from conference abstracts, non-peer-reviewed sources, or studies with limited methodological reporting. Other sources of potential bias include the different definitions of obesity used in the included publications and the epidemiological data sources used, because estimations of the prevalence of obesity were, in many instances, based on self-reporting, which may underestimate the true prevalence of obesity, and there is the potential for coding errors in electronic health records. It should also be noted that there is the potential for cohort overlap among the included publications. In particular, several publications utilized Spanish primary healthcare data, including the IBERICAN registry and the studies from Trujillo-Garrido et al., and the IMPACT-O studies used data from a longitudinal electronic medical records database including data from primary care providers and specialists. This may have introduced a risk of duplication bias or double counting, as patient-level data were not available. However, results from each publication are reported narratively and separately throughout this review, rather than pooled or synthesized quantitatively, and therefore any such overlap is not expected to affect the overall conclusions. Conclusions This SLR consolidates and synthesizes the available evidence on the epidemiology of obesity in Spain, the extensive clinical burden driven by associated comorbidities, and the substantial humanistic and economic impact, and demonstrates that important barriers still hinder proper identification and effective management of obesity as a chronic disease. Our results underscore the importance of early prevention of obesity, improvements in communication between HCPs and PwO, medical education, and implementation of a patient-centered multidisciplinary approach as part of integrated, individualized management of the disease to improve patient clinical outcomes and to avoid escalating the burden of obesity on both PwO and the national healthcare system. Ethics Ethical review and approval were not required because this study was an SLR of previously published literature and did not involve direct participation of human subjects. Key takeaway clinical messages •Obesity management in Spain remains hindered by stigma, low mood/depression among PwO, insufficient funding/resources/education, and obesity being considered a lifestyle condition rather than a chronic disease. Obesity management in Spain remains hindered by stigma, low mood/depression among PwO, insufficient funding/resources/education, and obesity being considered a lifestyle condition rather than a chronic disease. •PwO are likely to require more healthcare resources than individuals without overweight/obesity, with ORCs contributing greatly to the economic burden of obesity on healthcare systems. PwO are likely to require more healthcare resources than individuals without overweight/obesity, with ORCs contributing greatly to the economic burden of obesity on healthcare systems. •A systematic gap exists between the documented burden of obesity in Spain and its identification, treatment and prioritization. A systematic gap exists between the documented burden of obesity in Spain and its identification, treatment and prioritization. Author contributions The authors provided substantial contributions to the conception and design of the work (Silvia Díaz-Cerezo, Esther Artime); the acquisition, analysis, or interpretation of data for the work (Jennifer Redondo-Antón, Silvia Díaz-Cerezo, Esther Artime, Miguel Ángel Rubio-Herrera); and drafting the work and/or revising it critically for important intellectual content (all authors) and gave final approval of the version to be submitted to and published in the journal (all authors). All authors have participated sufficiently in the work to take public responsibility for appropriate portions of the content and have agreed to be accountable for all aspects of the work. Data availability The datasets generated during and/or analyzed during the current study are available from the corresponding author upon reasonable request. AI declaration During the preparation of the initial draft of this work, AI-assisted copy editing was used, but subsequent drafts did not use any AI. The authors reviewed and edited the content as needed and take full responsibility for the content of the publication. Source of funding This work was funded by Eli Lilly and Company. Declaration of competing interests Jennifer Redondo-Antón, Silvia Díaz-Cerezo, Esther Artime and Miriam Rubio-de Santos are employees and minor shareholders of Eli Lilly and Company. Miguel Ángel Rubio-Herrera has no conflicts of interest to declare. Acknowledgments Medical writing support during preparation of the initial draft was provided by Alberto García Mariscal at Evidenze Health España S.L.U. Subsequent drafts of the manuscript were prepared by Marie Cheeseman and Sheridan Henness PhD (Rx Communications, Mold, UK), under the direction of the authors. Footnotes Supplementary data to this article can be found online at https://doi.org/10.1016/j.obpill.2026.100334. Supplementary data The following is the Supplementary data to this article: Multimedia component 1 References Associated Data Supplementary Materials Multimedia component 1 Data Availability Statement The datasets generated during and/or analyzed during the current study are available from the corresponding author upon reasonable request.